Sign In
Buy ZLAB
$17.17
+0.0200 (+0.117%)
At Close: Jun 03, 2026
Why Shares of Zai Lab Soared This Week
03:50pm, Thursday, 05'th Jan 2023
A strong phase-3 clinical trial boosted investors' hopes for the Chinese biotech company.
What's Going On With Zai Lab Stock - Zai Lab (NASDAQ:ZLAB)
09:26am, Wednesday, 04'th Jan 2023
Zai Lab Ltd - ADR ZLAB shares are trading higher by 7.04% to $33.01 Wednesday morning. Shares of Chinese companies at large are trading higher after Chinese regulators reportedly approved a capital ra
Zai Lab Announces Participation in January Investor Conferences
07:30am, Tuesday, 20'th Dec 2022
SHANGHAI, China and CAMBRIDGE, Mass., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, t
Zai Labs: Biopharma's Alibaba, But Better
01:59pm, Tuesday, 13'th Dec 2022
Zai Lab Limited is a relative new entrant to the Chinese pharma space and has multiple approvals and a large clinical pipeline. Founder Samantha Du seems willing and capable at driving commercializati
Zai Lab Limited (ZLAB) Q3 2022 Earnings Call Transcript
11:40am, Thursday, 10'th Nov 2022
Zai Lab Limited (NASDAQ:ZLAB ) Q3 2022 Results Conference Call November 10, 2022 8:00 AM ET Company Participants Billy Cho - Chief Financial Officer Samantha Du - Founder, Chairperson and Chief Execut
Deal Activity Could Jumpstart Biotechnology
11:35pm, Monday, 31'st Oct 2022
Recent clinical successes and M&A could bring interest back to biotechnology, especially among mid-capitalization names with derisked or approved products. Restructuring, corporate activity, and COVID
Zai Lab Announces Participation in November Investor Conferences
07:52am, Monday, 31'st Oct 2022
SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical
Zai Lab to Announce Third Quarter 2022 Financial Results on November 9, 2022
07:30am, Tuesday, 18'th Oct 2022
-- Company to Host Conference Call and Webcast on November 10, 2022, at 8:00 a.m. ET -- Company to Host Conference Call and Webcast on November 10, 2022, at 8:00 a.m. ET
New subgroup analysis of the Phase 3 PRIME study reveals improvement in efficacy outcomes for ZEJULA® (niraparib) maintenance treatment when started within 12 weeks after first-line platinum-based ch
Zai Lab Announces Participation in September Investor Conferences
07:30am, Tuesday, 23'rd Aug 2022
SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical
Zai Lab Limited's (ZLAB) CEO Samantha Du on Q2 2022 Results - Earnings Call Transcript
02:16pm, Wednesday, 10'th Aug 2022
Zai Lab Limited (NASDAQ:ZLAB ) Q2 2022 Earnings Conference Call August 10, 2022 8:00 AM ET Company Participants Samantha Du - Founder, Chairperson and Chief Executive Officer Josh Smiley - Chief Opera
Tesla, Twitter And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
11:27am, Wednesday, 10'th Aug 2022 Benzinga
The Trade Desk, Inc. (NASDAQ: TTD) rose 17.3% to $63.90 in pre-market trading after the company reported better-than-expected Q2 sales results and issued Q3 sales guidance above estimates.
Synalloy Co
Why Earnings Season Could Be Great for Zai Lab (ZLAB)
05:07pm, Monday, 08'th Aug 2022 Zacks Investment Research
Zai Lab (ZLAB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Why Earnings Season Could Be Great for Zai Lab (ZLAB)
02:18pm, Monday, 08'th Aug 2022
Zai Lab (ZLAB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia
11:02am, Monday, 08'th Aug 2022 GlobeNewswire Inc.
Trial met primary endpoint, with KarXT demonstrating a statistically significant 9.6-point reduction in PANSS Total Score compared to placebo at Week 5 (p<0.0001)
